Business
Medicenna Announces Changes to Board Composition
TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announces that Mr. Richard Sutin and Mr. Angelos Georgakis have been appointed, effective as of February 12, 2026, to the board of directors of the Company (the “Board”). “We are excited to welcome Mr. Richard Sutin and Mr. Angelos Georgakis to the Medicenna board of directors
About this update from Medicenna Therapeutics Corp.
[{"type":"image","alt":"Medicenna Therapeutics Corp.","displaySize":"","headline":null,"caption":"Medicenna Therapeutics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/33fcbf6dc1c4c8dceac4cdb8f9da49c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iKkUSgUQdlNQdX43zhjRLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/33fcbf6dc1c4c8dceac4cdb8f9da49c2","width":300,"height":38}},"lazy":false},{"type":"text","content":"TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announces that Mr. Richard Sutin and Mr. Angelos Georgakis have been appointed, effective as of February 12, 2026, to the board of directors of the Company (the “Board”).","length":393,"tagName":"p"},{"type":"text","content":"“We are excited to welcome Mr. Richard Sutin and Mr. Angelos Georgakis to the Medicenna board of directors” commented Dr Fahar Merchant, President and CEO of Medicenna. “Mr. Sutin’s extensive knowledge in capital markets and mergers and acquisitions, and Mr. Georgakis’ experience in advising biotech leadership through critical inflection points make them outstanding additions to our Board. Their expertise and strategic acumen will be instrumental in advancing our Company’s growth and stewardship in the future. We look forward to benefiting from their insights and experiences to create long-term value for our stakeholders.”","length":630,"tagName":"p"},{"type":"text","content":"Mr. Sutin and Mr. Georgakis’s appointments to the Board follow the retirement, effective as of February 12, 2026, of Ms. Karen Dawes, who has served on the Board since 2019, most recently as Chair of the Compensation Committee and as a member of the Audit Committee.","length":266,"tagName":"p"},{"type":"text","content":"The Board wishes to thank Ms. Dawes for her contributions to the Company during her tenure as a director of Medicenna. She has played an important role in guiding the Company to its current position within the industry.","length":219,"tagName":"p"},{"type":"text","content":"“On behalf of myself and our Board, I want to thank Karen for all of her work, commitment an...